Pandion Therapeutics Holdco
| General Information | |
| Business: |
We are a clinical stage biopharmaceutical company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases. We have combined a network-based conceptualization of the immune system with expertise in advanced protein engineering to develop our TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform. Our TALON platform enables us to employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. |
| Industry: | PHARMACEUTICAL PREPARATIONS |
| Employees: | 43 |
| Founded: | 2016 |
| Contact Information | |
| Address | 134 Coolidge Avenue, Watertown, MA 02472, US |
| Phone Number | (617) 393-5925 |
| Web Address | http://www.pandiontx.com |
| View Prospectus: | Pandion Therapeutics Holdco |
| Financial Information | |
| Market Cap | $475.9mil |
| Revenues | $2.97 mil (last 12 months) |
| Net Income | $-27.0 mil (last 12 months) |
| IPO Profile | |
| Symbol | PAND |
| Exchange | NASDAQ |
| Shares (millions): | 7.5 |
| Price range | $18.00 - $18.00 |
| Est. $ Volume | $119.0 mil |
| Manager / Joint Managers | Goldman Sachs/ Morgan Stanley/ SVB Leerink/ BMO Capital Markets |
| CO-Managers | - |
| Expected To Trade: | 7/17/2020 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |